$0.36
-0.02 (-4.56%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CTSO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 3 observational · 5 with posted results
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC) · FINRA short interest 38.3 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CytOSorb TreatMent Of Critically Ill PatientS RegistryNCT05146336observationalICU mortality | — | Recruiting | Device: CytoSorb | Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis, Cardiogenic Shock, Pancreatitis, Acute on Chronic Liver Failure, Acute Liver Failure, Burns, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS), Extracorporeal Life Support, Postoperative Endocarditis, Hemophagocytic Lymphohistiocytoses, Liver Transplant; Complications, Infectious Disease, Postoperative Vasoplegic Syndrome, Drug Overdose, Sepsis | 3,000 | Jun 2032 | ≤ 2,142 d | 2025-09-11 |
| Safe and Timely Antithrombotic Removal (STAR) RegistryNCT05077124observationalBleeding complications including requirements for transfusions and other blood products | — | Recruiting | Device: CytoSorb | Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative | 1,000 | 2025-09-30 | — | 2025-07-16 |
| Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)NCT05093504results2025-05-04Incidence of Perioperative BleedingRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor's decision for business reasons. | Device: Sham comparator, DrugSorb-ATR system | Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative | 9 | 2024-01-29actual | — | 2025-05-04 |
| Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)NCT04976530results2025-04-11Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) PopulationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: DrugSorb-ATR system, Sham comparator | Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative | 140 | 2023-08-07actual | — | 2025-04-11 |
| Registry of CytoSorb Therapy in COVID-19 ICU PatientsNCT04391920observationalICU mortality | — | Completed | Device: CytoSorb 300 mL device | COVID-19 | 138 | 2022-01-20actual | — | 2024-02-09 |
| CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac SurgeryNCT03384875results2024-12-04Incidence and Severity of Acute Kidney Injury (AKI) in the First 48 Hours After Cardiopulmonary Pulmonary Bypass (CPB)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor's decision for business reasons | Device: CytoSorb | Elective Cardiac Surgery | 186 | 2022-01-18actual | — | 2024-12-04 |
| Ticagrelor CytoSorb HemoadsorptionNCT04131959results2022-03-09Primary Pharmacodynamic EndpointOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Stalled study execution from the impact of the COVID-19 pandemic on the UK NHS | Device: CytoSorb 300 mL device | Emergent Cardiothoracic Surgery, Bleeding, Drug Removal | 5 | 2021-05-04actual | — | 2022-03-09 |
| CytoSorb Reduction of Free Hemoglobin During Cardiac SurgeryNCT02566525results2021-08-20Assessment of Serious Device Related Adverse EventsRandomized · Open-label · Treatment | Not applicable | Completed | Device: CytoSorb | Elective Cardiac Surgery | 52 | Oct 2016actual | — | 2021-08-20 |
| Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With RhabdomyolysisNCT02111018Efficacy of device as measured by change in myoglobinRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Lack of enrollment | Device: CytoSorb Device · Procedure: CVVH | Rhabdomyolysis | 0 | Jun 2016 | — | 2023-04-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19